Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Rejects Eisai’s Aquavan Injection

This article was originally published in The Pink Sheet Daily

Executive Summary

Advisory panel had voted in favor of propofol prodrug, with conditions; timeline for sedative’s resubmission is uncertain.

You may also be interested in...



Eisai Wins Approval Of Sedative Lusedra, But Without Main Marketing Advantage

Company was hoping to position Lusedra as an anesthetic that did not require the presence of an anesthesiologist.

Eisai Wins Approval Of Sedative Lusedra, But Without Main Marketing Advantage

Company was hoping to position Lusedra as an anesthetic that did not require the presence of an anesthesiologist.

Shionogi Gains U.S. Sales Force With $1.4 Billion Sciele Acquisition

Shionogi offers strong pipeline, Sciele brings 770-strong sales force to Japan-U.S. pairing.

Related Content

Topics

UsernamePublicRestriction

Register

PS068148

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel